Home › Funds › Dundas Partners LLP › ABT

Dundas Partners LLP position in ABT

ABBOTT LABORATORIES · Health Care

Dundas Partners LLP reported holding 398,265 shares of ABT (ABBOTT LABORATORIES) in its Q3 2026 13F filing — a position valued at US$39.4M, representing 3.12% of its reported portfolio and ranking #14 among its reported holdings. Dundas Partners LLP has disclosed ABT holdings in 13 of the last 13 reported quarters, going back to Q3 2023.

Latest position (Q3 2026)398.26K sh
Reported value held$39.36M
Portfolio Weight3.12%
First reportedQ3 2023
Last changeReduce
Updated2026-11-13

Last updated: 2026-11-13 · Source: SEC EDGAR Form 13F-HR

How Dundas Partners LLP's ABT position evolved

Dundas Partners LLP first disclosed a stake in ABT in Q3 2023 at 323,330 shares (US$31.3M). The position peaked in Q3 2025 at 442,954 shares, worth US$59.3M. Across 13 filings, Dundas Partners LLP increased the stake 4 time(s), trimmed it 3 time(s) and left it unchanged 5 time(s). The most recent filing (Q3 2026) shows 398,265 shares valued at US$39.4M — a reduction of -25,668 shares quarter over quarter..

Quarter by quarter

QuarterSharesValueChange
Q3 2023 323.33K $31.32M New
Q4 2023 323.33K $35.59M Hold
Q1 2024 323.33K $36.75M Hold
Q2 2024 330.23K $34.31M Add
Q3 2024 345.05K $39.34M Add
Q4 2024 345.05K $39.03M Hold
Q1 2025 345.05K $45.77M Hold
Q2 2025 371.71K $50.56M Add
Q3 2025 442.95K $59.33M Add
Q4 2025 428.31K $53.66M Reduce
Q1 2026 423.93K $43.53M Reduce
Q2 2026 423.93K $38.47M Hold
Q3 2026 398.26K $39.36M Reduce

Dots on the line are colored by change type; missing quarters mean no position was reported.

About ABT and 13F data

ABT (ABBOTT LABORATORIES) is a Health Care company. 21 other funds we track also report a position in ABT — the largest reported positions include Vanguard Group (US$22.00B), Charles Schwab Investment Management (US$5.41B), CHARLES SCHWAB INVESTMENT MANAGEMENT INC (US$5.41B). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding ABT

All ABT fund holders →

FAQ

How long has Dundas Partners LLP held ABT?

Dundas Partners LLP has disclosed ABT holdings in 13 of the last 13 reported quarters, going back to Q3 2023.

What is Dundas Partners LLP's current position in ABT?

As of Q3 2026, Dundas Partners LLP holds 398.26K shares of ABT (ABBOTT LABORATORIES), valued at $39.36M, representing 3.12% of its reported portfolio and ranking #14.

Has Dundas Partners LLP been buying or selling ABT?

In the latest 13F filing (Q3 2026), Dundas Partners LLP reduced its position in ABT. The position peaked in Q3 2025 at 442.95K shares.

Which other funds hold ABT?

Other major institutional holders of ABT include Vanguard Group, Charles Schwab Investment Management, CHARLES SCHWAB INVESTMENT MANAGEMENT INC, among 21 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.